Deputy of Research & Technology, Ardabil University of Medical Sciences, Ardabil, Iran; Pharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Pharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran; Department of Pharmacology, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
Int Immunopharmacol. 2021 Mar;92:107051. doi: 10.1016/j.intimp.2020.107051. Epub 2020 Sep 29.
The worldwide outbreak of SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 as a novel human coronavirus, was the worrying news at the beginning of 2020. Since its emergence complicated more than 870,000 individuals and led to more than 43,000 deaths worldwide. Considering to the potential threat of a pandemic and transmission severity of it, there is an urgent need to evaluate and realize this new virus's structure and behavior and the immunopathology of this disease to find potential therapeutic protocols and to design and develop effective vaccines. This disease is able to agitate the response of the immune system in the infected patients, so ARDS, as a common consequence of immunopathological events for infections with Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, and SARS-CoV-2, could be the main reason for death. Here, we summarized the immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2 and therapeutic and prophylactic strategies with a focus on vaccine development and its challenges.
2020 年初,新型人类冠状病毒——严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引发的全球疫情,是令人担忧的新闻。自出现以来,它已导致全球超过 87 万人感染,超过 4.3 万人死亡。鉴于其潜在的大流行威胁和传播严重程度,迫切需要评估和了解这种新病毒的结构和行为以及疾病的免疫病理学,以寻找潜在的治疗方案,并设计和开发有效的疫苗。这种疾病能够激活感染患者免疫系统的反应,因此,ARDS(急性呼吸窘迫综合征)是中东呼吸综合征冠状病毒(MERS-CoV)、SARS-CoV 和 SARS-CoV-2 感染后免疫病理事件的常见后果,可能是死亡的主要原因。在这里,我们总结了 SARS-CoV、MERS-CoV 和 SARS-CoV-2 的免疫反应和免疫逃避特征,以及治疗和预防策略,重点介绍了疫苗开发及其面临的挑战。